Quinoline compound or pharmaceutically acceptable salt thereof for treating giant-cell tumor of bone

Abstract

The invention belongs to the field of medicines, and provides a quinoline compound or a pharmaceutically acceptable salt thereof for treating the giant-cell tumor of bone. Specifically, the inventionrelates to the application of a therapeutically effective amount of a quinoline compound I or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating the giant-cell tumorof bone, the application of a combination of a therapeutically effective amount of the quinoline compound I or the pharmaceutically acceptable salt thereof and a second therapeutic agent in preparation of a combined medicine for treating the giant-cell tumor of bone. The chemical name of the quinoline compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.

Description

technical field [0001] The invention belongs to the field of medicine, and the invention belongs to the technical field of pharmaceutical preparations, specifically quinoline compounds or pharmaceutically acceptable salts thereof for treating giant cell tumor of bone, and quinoline compounds for combined treatment of giant cell tumor of bone or a pharmaceutically acceptable salt thereof. Background technique [0002] Giant cell tumor of bone (Giant Cell Tumor Of Bone, GCT) is a type of tumor with high osteolytic destruction and local invasiveness, very few have reactive new bone formation and self-healing tendency, and can form soft tissue package through bone cortex piece. Giant cell tumor of bone has a relatively high incidence in my country, ranking third among primary bone tumors, accounting for about 4-12% of all primary bone tumors, significantly higher than that in European and American countries, accounting for 18-23% of benign bone tumors . Although most giant cel...

AI Technical Summary

Problems solved by technology

However, several problems cannot be avoided in surgical operations: incomplete curettage and difficulty in complete surgical resection; high recurrence rate; tumor hematogenous metastasis caused by surgical extrusion; difficulty in limb function reconstruction; early and late complications of artificial joint replacement, etc.

For patients with postoperative recurrence, due to the change of anatomical structure and the upgrading of tumor malignancy, the difficulty of re-operation is significantly increased, and even surgery cannot be performed.

Compared with other bone tumors such as osteosarcoma, giant cell tumor of bone has slightly poorer chemotherapy sensitivity, less choice of drugs, and slower chemotherapy progress.

Images